Advertisement

Topics

With its planned acquisition of Biscayne Neurotherapeutics, Supernus Pharmaceuticals ($SUPN) adds a Phase I epilepsy candidate to its portfolio of CNS treatments: http://ow.ly/Q6DP30lP4zt 

17:55 EDT 14 Sep 2018 | Genetic Engineering News

With its planned acquisition of Biscayne Neurotherapeutics, Supernus Pharmaceuticals ($SUPN) adds a Phase I epilepsy candidate to its portfolio of CNS treatments: http://ow.ly/Q6DP30lP4zt 

Original Article: With its planned acquisition of Biscayne Neurotherapeutics, Supernus Pharmaceuticals ($SUPN) adds a Phase I epilepsy candidate to its portfolio of CNS treatments: http://ow.ly/Q6DP30lP4zt 

NEXT ARTICLE

More From BioPortfolio on "With its planned acquisition of Biscayne Neurotherapeutics, Supernus Pharmaceuticals ($SUPN) adds a Phase I epilepsy candidate to its portfolio of CNS treatments: http://ow.ly/Q6DP30lP4zt "

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...